




PHARMACEUTICAL 2017

ARRAY BIOPHARMA INC Rank 233 of 292





PHARMACEUTICAL 2017

ARRAY BIOPHARMA INC Rank 233 of 292

The relative strengths and weaknesses of ARRAY BIOPHARMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARRAY BIOPHARMA INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 46% points. The greatest weakness of ARRAY BIOPHARMA INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 145% points.

The company's Economic Capital Ratio, given in the ranking table, is -84%, being 87% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	155,301
Cost of Goods Sold	23,166
Intangible Assets	0
Liabilities, Current	52,434
Liabilities, Non-Current	154,398
Other Assets	6,919
Other Compr. Net Income	2.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-10,631
Other Revenues	137,879
Property and Equipment	6,680
Research and Development	160,655
Selling, General and Administrative Expense	36,267

Output Variable	Value in 1000 USD
Assets	168,900
Liabilities	206,832
Expenses	220,088
Revenues	137,879
Stockholders Equity	-37,932
Net Income	-92,840
Comprehensive Net Income	-92,839
Economic Capital Ratio	-84%